MoneyBall Medicine-logo

MoneyBall Medicine

Health & Wellness Podcasts

The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends are improving healthcare delivery and efficiency. And now he brings you intimate conversations with industry pioneers—like Mount Sinai's Joel Dudley, N-of-One's Jennifer Carter, Semeion's Massimo Buscema, Genetic Alliance's Sharon Terry, and many more—who share their hard-won experience in the surprising, exciting, untamed world of data-driven healthcare.

The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends are improving healthcare delivery and efficiency. And now he brings you intimate conversations with industry pioneers—like Mount Sinai's Joel Dudley, N-of-One's Jennifer Carter, Semeion's Massimo Buscema, Genetic Alliance's Sharon Terry, and many more—who share their hard-won experience in the surprising, exciting, untamed world of data-driven healthcare.

Location:

United States

Description:

The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends are improving healthcare delivery and efficiency. And now he brings you intimate conversations with industry pioneers—like Mount Sinai's Joel Dudley, N-of-One's Jennifer Carter, Semeion's Massimo Buscema, Genetic Alliance's Sharon Terry, and many more—who share their hard-won experience in the surprising, exciting, untamed world of data-driven healthcare.

Twitter:

@hglorikian

Language:

English

Contact:

617-407-5093


Episodes

Jeff Booth on the Power of Falling Prices in Technology and Healthcare

9/30/2020
What if all our everyday assumptions about economics are wrong? This week Harry speaks with author and entrepreneur Jeff Booth, who says the most powerful force for change in the future will be deflation: getting more for less. Even the healthcare industry will feel the effects, he says. Listen to find out how. Booth is the author of The Price of Tomorrow: Why Deflation is the Key to an Abundant Future. The book argues that the most powerful force for innovation and change is not endless...

Duration:00:57:16

How Drug Development Guru Mark Eller Went from AI Skeptic to AI Supporter

9/14/2020
How does an expert in pharmacokinetics, whose only exposure to computers was taking one semester of programming in college to meet a language requirement, become an advocate for the new AI-driven style of drug discovery? This week Harry finds out from Mark Eller, who helped to invent Allegra at Hoechst Marion Roussel (now Sanofi), spent 12 years at Jazz Pharmaceuticals, and is now senior vice president of research and development at twoXAR, an AI-driven drug discovery startup. In our...

Duration:00:41:58

Andrew A. Radin Returns with a Progress Report on twoXAR

8/31/2020
Harry welcomes back Andrew A. Radin, CEO of the drug discovery startup twoXAR, where scientists model pathogenesis computationally to identify potential drug molecules, ideally shaving years off the drug development process. Harry first spoke with Radin two years ago at the AI Applications Summit—Biopharma. (Listen back to MoneyBall Medicine Episode 9 from November 2018 for more details about the company's innovations.) Since then, the company has begun to use what Radin calls twoXAR's...

Duration:00:56:58

Rayid Ghani Explains How AI Can Both Predict and Shape Patient Behavior

8/20/2020
In this week's show Harry interviews Rayid Ghani, a computer scientist at Carnegie Mellon University who studies how to use AI and data science to model and influence people's behavior in realms like politics, healthcare, education, and criminal justice. Ghani tell Harry he grew up hating coding, since the very need for it showed that "computers are really stupid and dumb." But Ghani says he eventually realized that machine learning can change that by allowing programmers to teach computers...

Duration:00:44:19

Oura's Harpreet Rai on a Ring That May Change Covid-19 Detection

8/3/2020
This week Harry speaks with Oura Health CEO Harpreet Rai, who's leading an effort to explore how a wearable sleep-monitoring device—the Oura Ring—can pick up patterns that may help diagnose covid-19 infections and other problems. The ring is equipped with sensors that measure heart rate and body temperature, as well as a tiny Bluetooth radio that syncs the data it collects with a smartphone app. The Finland-based company designed the ring primarily to measure sleep quality, but it also...

Duration:00:46:13

David Sable on the Genetic Revolution in Fertility Treatment

7/20/2020
David Sable got his start in reproductive medicine in the late 1980s, a time when he says fertility treatments were "very primitive." But by the mid-2000s, he says, new procedures and new insights into the genetics of development had changed everything. His subsequent time observing (and investing in) the field has convinced him that reproductive medicine is "the most interesting area of medicine this century." Sable is a medical and entrepreneurial chameleon who trained in obstetrics and...

Duration:00:48:58

Elli Papaemmanuil Explains How Genomics Will Transform Cancer Care

6/29/2020
This week Harry speaks with molecular geneticist Elli Papaemmanuil about how newly available genomic data could lead to major improvements in the standard of care for cancer patients, leading to an age of true precision medicine. Papaemmanuil is an assistant professor of computational oncology at Memorial Sloan Kettering Cancer Center in New York. Her lab's research is built around the idea that the genetic sequences of tumor cells reveal distinctive acquired mutations that can allow...

Duration:00:51:51

Gregory Bowman Explains How You Can Help Cure the Coronavirus from Home

6/17/2020
This week Harry interviews Gregory Bowman, an associate professor in the department of biochemistry and molecular biophysics in the School of Medicine at Washington University in St. Louis. Bowman is the current director of Folding@home, a distributed computing project currently focused on analyzing the structures of coronavirus proteins to find targets for new drug therapies that could help end the pandemic. Understanding and modeling the 3D structures of tiny, ever-shifting protein...

Duration:00:32:43

Covid-19 Tracing Inside Companies, with SaferMe's Clint Van Marrewijk

6/1/2020
Harry's guest this week is the founder and CEO of a New Zealand firm, SaferMe, that had developed proximity-based smartphone apps for worker safety. When the coronavirus came along, their apps turned out to be a great way to help companies build their own "contact tables" to identify, test, and isolate SARS-CoV-2 carriers. In epidemiology, contact tracing is the art of determining who has crossed paths with an infected individual, so that those exposed can be alerted and can take...

Duration:00:29:53

Ulo Palm on P-Values: What They Are and Why They're Past Their Prime

5/20/2020
Though the p-value "determines everything we do in drug development or medical research," says Dr. Ulo Palm , it may be one of the most misunderstood and misused quantities in experimental science—drug discovery included. At its core, the p-value shows the probability that an observed effect was due to random chance. In other words, if a drug seems to outperforms a placebo with an associated p-value of 0.05, there's only a 5 percent chance that the study was wrong and that the drug is, in...

Duration:00:42:46

How Data Is Critical to Engineering Antibodies to Block COVID-19

4/16/2020
Building on his March 2020 interview with Jake Glanville, the founding partner and CEO of South San Francisco-based computational antibody engineering startup Distributed Bio, Harry speaks with three company scientists in the trenches: JP Buerckert, director of computational immunology, and Shahrad Daraekia and Jack Wang, both senior scientists. Together they're working on projects such as engineering existing human antibodies to the SARS virus so that they'll also work against the novel...

Duration:00:34:35

Jacob Glanville Confronts Coronavirus Through Immuno-engineering

3/9/2020
If you've seen the recent Netflix docu-series "Pandemic," about efforts to check previous viral outbreaks, you've seen former Pfizer scientist Jacob Glanville in action. The inventor, entrepreneur, and Ph.D. immunologist capitalized on the advent of cloud computing to provide vaccine and drug developers with high-throughput genomic sequencing of antibodies in humans and other species. He calls it "using the ability to look deep into these maelstroms of antibodies to try to understand why...

Duration:00:54:16

Ramy Farid on the Power of Computation in Drug Discovery

3/3/2020
Schrödinger makes software that models the physics of atomic-scale interactions to predict the chemical properties of candidate drug molecules, helping its customers speed up drug discovery. A decade ago, Farid tells Harry, the company faced the chicken-and-egg challenge of convincing customers that its computational platform works, so that they would scale up their commitment, so that they could gather evidence it was working. Close collaborations with customers like Nimbus Therapeutics...

Duration:00:28:24

Illumina's Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks

2/5/2020
Rapid sequencing of viral genomes is giving physicians and epidemiologists new ways to identify, track, and potentially slow outbreaks of viral infections such as the novel Wuhan coronavirus. That means high-throughput genome sequencing—which had predominantly been a research tool—is taking its place as a front-line weapon in the fight to prevent pandemics, says Febbo, a medical oncologist. "Last year, 40 percent of our consumables in sequencing were for clinical testing, and we see the...

Duration:00:28:09

Daniella Gilboa on How Deep Learning Can Revolutionize IVF

1/27/2020
Doctors helping couples conceive through in-vitro fertilization typically must screen multiple fertilized embryos to select one embryo for implantation—but the process is fraught with risk and subjectivity. from In 2018 Gilboa and her colleagues Daniel Seidman and Eyal Schiff co-founded AIVF, an Israel-based startup developing decision support tools that use deep learning and computer vision to lower the risk by identifying the most promising embryos for intrauterine implantation. The...

Duration:00:30:28

Tom Davenport on the Analytics Gap in Healthcare

1/3/2020
Tom Davenport knows analytics, big data, and AI—he teaches executive courses on the subject at Babson College, Harvard Business School, the Harvard School of Public Health, and the MIT Sloan School of Management, and is widely known for his books on analytics and AI in business, Competing on Analytics (2007), Only Humans Need Apply (2016), and The AI Advantage (2018). Davenport notes that a number of life science startups are attempting to use machine learning, big data, and AI to reinvent...

Duration:00:31:26

Milind Kamkolkar on Seeing the Forest and the Trees at Cellarity

12/16/2019
Milind Kamkolkar joined Cellarity in January 2019 to help the company to prove that it is now possible to "encode a cell" digitally—to use big data, deep learning, and other methods to model many different interconnected networks of molecular interactions. "The whole idea...is really only feasible now," he says. "What changed over the last number of years is the ability to compute at scale." The promise of Cellarity's computational models, Kamkolkar says, is that they look broadly at cell...

Duration:00:37:54

Alan Copperman on How Data is Transforming Reproductive Medicine

11/26/2019
Dr. Alan Copperman is director of the Division of Reproductive Endocrinology and Infertility and Vice Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at the Mount Sinai Health System. He's also a clinical professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai; medical director of Reproductive Medicine Associates of New York, one of the world's leading IVF centers; chief medical officer at Semaphore Genomics,...

Duration:00:26:47

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery

11/5/2019
Gini Desphande says she likes to think of "AI" as augmented intelligence rather than artificial intelligence: a system of human plus machine intelligence that can speed up drug development and cut R&D costs and failure rates in clinical trials. AI "really isn't at the point where it's automatable," she says. "We still need a lot of human intelligence to be coupled with this technology, to determine what are the questions you want to ask and to evaluate all the targets that come out, to say...

Duration:00:28:07

Chris Boone of Pfizer on Being a Data Hippie

10/25/2019
Dr. Chris Boone, vice president and lead for global medical epidemiology and big data analysis at Pfizer, is a health futurist, social entrepreneurs, executive, professor, patient advocate, and self-proclaimed "data hippie." He says he long aimed to be CEO of a health system, but eventually embraced his "true self" as a student of informatics, business intelligence, and big data analytics. "I come into the world of pharma not as a conventional or traditional pharma guy but as someone who...

Duration:00:36:54